A. Kamal Rath Eley Clancy; Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA.

138 SCIENTIFIC SESSIONS September 9-12 | ------------------------------------------------------------------------------------------------------------------------------------------------------ Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 161A Poster Session Clinical Pharmacology of Antiviral and Anti-Tubercu- losis Agents Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-1243 PharmacokineticPharmacodynamic Model for Neuramini- dase Inhibitor Oseltamivir in the Ferret K. Yang 1,2 , G. Rao 1,2 , M. Reddy 2 , C. Pamulapati 2 , B. M. Marathe 3 , E. A. Govorkova 3 , C. R. Rayner 2 , A. Forrest 1 ; 1 SUNY Buffalo, Buffalo, NY, 2 Roche, Nutley, NJ, 3 St. Jude Children’s Res. Hosp., Memphis, TN. A-1244 Population Pharmacokinetics PPK of Oseltamivir in Pedi- atric and Adult Subjects

M. A. Kamal

1 , S. A. Van Wart 2 , C. R. Rayner 1 , V. Subramoney 1 , D. K. Reynolds 2 , C. C. Bulik 2 , P. F. Smith 1 , S. M. Bhavnani 2 , A. Forrest 2 ; 1 Hoffman-LaRoche, Nutley, NJ, 2 ICPD, Latham, NY. A-1245 A Prospective, Open-Label Study of the Pharmacokinetics, Safety and Pharmacodynamics of Oseltamivir in Infants 1 Year with Influenza

B. Rath

1 , B. Clinch 2 , D. Abadir 3 , J. Brzostek 4 , C. Chappey 5 , A. Charoin- Pannier 6 , K. Klumpp 3 , V. Niranjan 7 , X. Tong 3 , M. Wollenhaupt 6 , C. R. Rayner 8 ; 1 Charite Univ. Med. Ctr., Berlin, Germany, 2 Roche Products Ltd, Welwyn, United Kingdom, 3 Hoffmann-La Roche, Inc., Nutley, NJ, 4 Zespol Opieki Zdrowotnej w Debicy, Debica, Poland, 5 Genentech, Inc., South San Francisco, CA, 6 F. Hoffmann-La Roche Ltd, Basel, Switzerland, 7 RxMD, Chennai, India, 8 Roche Products Pty Ltd, Melbourne, Australia. A-1246 Intravenous Zanamivir Has No Effect on Cardiac Repolar- ization in Healthy Subjects P. Patel, Y. Lou, S. Weller, J. Gan, E. Gould, A. Peppercorn; GlaxoSmith- Kline, Research Triangle Park, NC. A-1247 Improved Bioavailability and Mitigated Food Effect for Asunaprevir ASV Utilizing a Lipid-Based Formulation: Similar Exposure with 100mg BID Softgel Capsule SGC Relative to 200mg BID of Phase 2 Tablet

T. Eley

1 , P. Chan 2,1 , O. Sverdlov 2 , B. He 2 , B. Bedford 2 , H. Kandoussi 2 , C. Vema-Varapu 2 , R. Perrone 2 , K. Sims 2 , I. Chang 2 , R. J. Bertz 2 ; 1 Bristol- Myers Squibb, Princeton, NJ, 2 BMS, Princeton, NJ. POSTER WALK Tuesday, September 11 | 11:15 a.m. - 12:15 p.m. | Halls A-C New Developments in Transplantation Convener: Emily A. Blumberg, MD - Professor of Medicine Perelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA. Presentations: Refractory KPC Carbapenemase-Producing Klebsiella pneu- moniae Bacteremia is Tolerated by Solid Organ Transplant Patients SOT Pts

C. Clancy; Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA.

Chronic High EBV Load Carriage Has Low Predictive Value to Detect Post-Transplant Lymphoproliferative Disorder PTLD in Solid-Organ Transplant Recipients

C. Gardiol; Univ. Hosp. Ctr. of Lausanne, Lausanne, Switzerland.